Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) play critical roles in the regulation of gene transcription. However, the absence of CDK12 and CDK13 inhibitors has hindered the ability to investigate the consequences of their inhibition in healthy cells and cancer cells. Here we describe the rational design of a first-in-class CDK12 and CDK13 covalent inhibitor, THZ531. Co-crystallization of THZ531 with CDK12–cyclin K indicates that THZ531 irreversibly targets a cysteine located outside the kinase domain. THZ531 causes a loss of gene expression with concurrent loss of elongating and hyperphosphorylated RNA polymerase II. In particular, THZ531 substantially decreases the expression of DNA damage response genes and key super-enhancer-associated transcription factor genes. Coincident with transcriptional perturbation, THZ531 dramatically induced apoptotic cell death. Small molecules capable of specifically targeting CDK12 and CDK13 may thus help identify cancer subtypes that are particularly dependent on their kinase activities.

  • Compound


  • Compound


  • Compound


  • Compound


  • Compound


  • Compound


  • Compound


  • Compound


  • Compound


  • Compound


  • Compound

    tert-butyl methyl(22-(5-methyl-2-oxoimidazolidin-4-yl)-3,17-dioxo-7,10,13-trioxa-4,16-diazadocosyl)carbamate

  • Compound


Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


Primary accessions

Gene Expression Omnibus

NCBI Reference Sequence

Protein Data Bank

Referenced accessions


  1. 1.

    RNA polymerase II. Annu. Rev. Biochem. 60, 689–715 (1991).

  2. 2.

    Progression through the RNA polymerase II CTD cycle. Mol. Cell 36, 541–546 (2009).

  3. 3.

    , & Defining mechanisms that regulate RNA polymerase II transcription in vivo. Nature 461, 186–192 (2009).

  4. 4.

    , & The carboxy terminal domain of RNA polymerase II and alternative splicing. Trends Biochem. Sci. 35, 497–504 (2010).

  5. 5.

    & Pause, play, repeat: CDKs push RNAP II's buttons. Transcription 4, 146–152 (2013).

  6. 6.

    & Controlling the elongation phase of transcription with P-TEFb. Mol. Cell 23, 297–305 (2006).

  7. 7.

    et al. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 24, 2303–2316 (2010).

  8. 8.

    , , , & Opposing effects of Ctk1 kinase and Fcp1 phosphatase at Ser 2 of the RNA polymerase II C-terminal domain. Genes Dev. 15, 3319–3329 (2001).

  9. 9.

    , & Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol. Cell. Biol. 26, 2736–2745 (2006).

  10. 10.

    , , & CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing. Biochem. Biophys. Res. Commun. 354, 735–740 (2007).

  11. 11.

    et al. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Mol. Cell. Biol. 35, 928–938 (2015).

  12. 12.

    et al. Cyclin-dependent kinase 12 increases 3′ end processing of growth factor-induced c-FOS transcripts. Mol. Cell. Biol. 35, 468–478 (2015).

  13. 13.

    , & 3′ end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells. Genes Dev. 28, 342–356 (2014).

  14. 14.

    & Expression, purification, and identification of associated proteins of the full-length hCDK12/CyclinK complex. J. Biol. Chem. 290, 1786–1795 (2015).

  15. 15.

    , & Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3′ end processing. Mol. Cell 13, 67–76 (2004).

  16. 16.

    et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25, 2158–2172 (2011).

  17. 17.

    , , & A DNA damage response system associated with the phosphoCTD of elongating RNA polymerase II. PLoS One 8, e60909 (2013).

  18. 18.

    et al. Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction. PLoS One 3, e1448 (2008).

  19. 19.

    et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. Nucleic Acids Res. 43, 2575–2589 (2015).

  20. 20.

    et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA 105, 17079–17084 (2008).

  21. 21.

    et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 74, 287–297 (2014).

  22. 22.

    , , & Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J. Biol. Chem. 289, 9247–9253 (2014).

  23. 23.

    , & Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas. Biochim. Biophys. Acta 1849, 1179–1187 (2015).

  24. 24.

    et al. The structure and substrate specificity of human Cdk12/Cyclin K. Nat. Commun. 5, 3505 (2014).

  25. 25.

    et al. Structural and functional analysis of the Cdk13/Cyclin K complex. Cell Rep. 14, 320–331 (2016).

  26. 26.

    , , & The crystal structure of human CDK7 and its protein recognition properties. Structure 12, 2067–2079 (2004).

  27. 27.

    et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616–620 (2014).

  28. 28.

    et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 18, 699–710 (2011).

  29. 29.

    et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26, 909–922 (2014).

  30. 30.

    et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159, 1126–1139 (2014).

  31. 31.

    et al. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat. Struct. Mol. Biol. 19, 1108–1115 (2012).

  32. 32.

    et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373–1377 (2014).

  33. 33.

    et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell 22, 209–221 (2012).

  34. 34.

    & RNA polymerase II transcription elongation and Pol II CTD Ser2 phosphorylation: A tail of two kinases. Nucleus 5, 224–236 (2014).

  35. 35.

    et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75–87 (2002).

  36. 36.

    et al. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J. 9, 3343–3351 (1990).

  37. 37.

    , & Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition. Nat. Commun. 3, 842 (2012).

  38. 38.

    et al. Discovery of potent and selective covalent inhibitors of JNK. Chem. Biol. 19, 140–154 (2012).

  39. 39.

    & A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra. J. Am. Soc. Mass Spectrom. 9, 225–233 (1998).

  40. 40.

    et al. Improved electrospray ionization efficiency compensates for diminished chromatographic resolution and enables proteomics analysis of tyrosine signaling in embryonic stem cells. Anal. Chem. 81, 3440–3447 (2009).

  41. 41.

    , & mzAPI: a new strategy for efficiently sharing mass spectrometry data. Nat. Methods 6, 240–241 (2009).

  42. 42.

    Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).

  43. 43.

    & How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204–1214 (2013).

  44. 44.

    et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235–242 (2011).

  45. 45.

    et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).

  46. 46.

    , , & Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).

  47. 47.

    et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367 (2011).

  48. 48.

    et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010).

  49. 49.

    The PyMOL Molecular Graphics System (Version 1.2r3pre, Schrödinger, LLC).

  50. 50.

    et al. Revisiting global gene expression analysis. Cell 151, 476–482 (2012).

  51. 51.

    et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).

  52. 52.

    , & Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009).

  53. 53.

    et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56–67 (2012).

  54. 54.

    , , & Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).

  55. 55.

    et al. Model-based analysis of ChIP–Seq (MACS). Genome Biol. 9, R137 (2008).

  56. 56.

    et al. RefSeq: an update on mammalian reference sequences. Nucleic Acids Res. 42, D756–D763 (2014).

  57. 57.

    et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334 (2013).

  58. 58.

    et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307–319 (2013).

Download references


We thank R. George, K. Wong, P. Hammerman, J. Bradner and members of the Gray and Young laboratories for helpful discussions. We thank P. Wisniewski and C. Zollo from the Whitehead FACS facility for help with FACS instruments. We thank J. Love, T. Volkert, and S. Gupta from the Whitehead Genome Core for help with genomics experiments. The authors would like to thank Diamond Light Source for beamtime (proposal mx8421), and the staff of Beamline I03 for assistance with data collection. We thank W. Massefski from the Dana–Farber NMR lab for help in collecting NMR data for the manuscript. M.G. is a member of the DFG excellence cluster ImmunoSensation. This work was supported by the National Institutes of Health (HG002668 and CA109901 to R.A.Y. and 5 R01 CA179483-02 C to N.S.G.), the Koch Institute and Dana–Farber/Harvard Cancer Center Bridge Grant (N.K., N.S.G., R.A.Y.), the DFG (GE 976/9-1 to M.G.), the Hope Funds for Cancer Research Grillo-Marxuach Family Fellowship (B.J.A.), and a NDM Prize Studentship, funded in part by the Medical Research Council (S.E.D.-C.). The SGC is a registered charity (no. 1097737) that receives funds from AbbVie, Bayer, Boehringer Ingelheim, Genome Canada through Ontario Genomics Institute Grant OGI-055, GlaxoSmithKline, Janssen, Lilly Canada, the Novartis Research Foundation, the Ontario Ministry of Economic Development and Innovation, Pfizer, Takeda, and Wellcome Trust Grant 092809/Z/10/Z.

Author information

Author notes

    • Tinghu Zhang
    • , Nicholas Kwiatkowski
    •  & Calla M Olson

    These authors contributed equally to this work.


  1. Department of Cancer Biology, Dana–Farber Cancer Institute, Boston, Massachusetts, USA.

    • Tinghu Zhang
    • , Nicholas Kwiatkowski
    • , Calla M Olson
    • , Scott B Ficarro
    • , Yanke Liang
    • , Theresa Manz
    • , Mingfeng Hao
    • , Jarrod A Marto
    •  & Nathanael S Gray
  2. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.

    • Tinghu Zhang
    • , Nicholas Kwiatkowski
    • , Calla M Olson
    • , Scott B Ficarro
    • , Yanke Liang
    • , Mingfeng Hao
    • , Jarrod A Marto
    •  & Nathanael S Gray
  3. Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA.

    • Nicholas Kwiatkowski
    • , Brian J Abraham
    • , Nancy M Hannett
    •  & Richard A Young
  4. Structural Genomics Consortium, University of Oxford, Oxford, UK.

    • Sarah E Dixon-Clarke
    • , Jonathan M Elkins
    •  & Alex N Bullock
  5. Department of Structural Immunology, Institute of Innate Immunity, University of Bonn, Bonn, Germany.

    • Ann K Greifenberg
    •  & Matthias Geyer
  6. Center of Advanced European Studies and Research, Bonn, Germany.

    • Ann K Greifenberg
    •  & Matthias Geyer
  7. Blais Proteomics Center, Dana–Farber Cancer Institute, Boston, Massachusetts, USA.

    • Scott B Ficarro
    •  & Jarrod A Marto
  8. Pharmaceutical and Medicinal Chemistry, Department of Pharmacy, Saarland University, Saarbrücken, Germany.

    • Theresa Manz
  9. Department of Biochemistry, Duke University Medical Center, Durham, North Carolina, USA.

    • Bartlomiej Bartkowiak
    •  & Arno L Greenleaf
  10. Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Richard A Young


  1. Search for Tinghu Zhang in:

  2. Search for Nicholas Kwiatkowski in:

  3. Search for Calla M Olson in:

  4. Search for Sarah E Dixon-Clarke in:

  5. Search for Brian J Abraham in:

  6. Search for Ann K Greifenberg in:

  7. Search for Scott B Ficarro in:

  8. Search for Jonathan M Elkins in:

  9. Search for Yanke Liang in:

  10. Search for Nancy M Hannett in:

  11. Search for Theresa Manz in:

  12. Search for Mingfeng Hao in:

  13. Search for Bartlomiej Bartkowiak in:

  14. Search for Arno L Greenleaf in:

  15. Search for Jarrod A Marto in:

  16. Search for Matthias Geyer in:

  17. Search for Alex N Bullock in:

  18. Search for Richard A Young in:

  19. Search for Nathanael S Gray in:


N.S.G., R.A.Y., N.K., and T.Z. conceived the project. N.S.G. and T.Z. conceived and directed chemistry effort with input from Y.L. Chemical synthesis and small molecule structure determination was performed by T.Z., M.H., and T.M. R.A.Y., N.S.G., B.J.A. and N.K. conceived genomics effort. N.K. and C.M.O. designed and executed cellular biological experimental research with input from N.S.G. and R.A.Y.S.E.D.-C. solved co-crystal structure of CDK12–cyclin K with THZ531 with guidance from J.M.E. and A.N.B. A.K.G. designed and executed CDK in vitro kinase assays with input from M.G. S.B.F. designed and performed protein mass spectrometry on THZ531–CDK12 adducts with input from J.A.M. N.M.H. provided cloning expertise. B.B. and A.L.G. developed and provided CDK12 and CDK13 antibodies. B.J.A. designed and performed genomics data analyses. N.K., T.Z., N.S.G. and R.A.Y. co-wrote the paper. All authors edited the manuscript.

Competing interests

N.S.G., T.Z., N.K. are inventors on patent applications covering THZ531 (WO 1421 2015/058126, WO/2014/063068, WO 2015/058140), which are licensed to a company Syros co-founded by N.S.G. and R.A.Y.

Corresponding authors

Correspondence to Richard A Young or Nathanael S Gray.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Results, Supplementary Figures 1–11 and Supplementary Tables 1–3.

  2. 2.

    Supplementary Note 1

    Synthetic Procedures

Excel files

  1. 1.

    Supplementary Data Set 1

    Mass spectrometry identifies CDK12-cyclin K and CDK13–cyclin K complexes as major targets of bioTHZ531 in Jurkat cell lysates.

  2. 2.

    Supplementary Data Set 2

    In vitro Ambit™ binding assay shows THZ531 potently inhibits CDK13.

  3. 3.

    Supplementary Data Set 3

    Gene expression microarray data of THZ531, Flavopiridol, THZ1-treated cells.

  4. 4.

    Supplementary Data Set 4

    Jurkat enhancers and super–enhancers identified by H3K27Ac ChIP–seq.

About this article

Publication history






Further reading